114 related articles for article (PubMed ID: 11018081)
1. Use of an antibody to target geldanamycin.
Mendelsohn J
J Natl Cancer Inst; 2000 Oct; 92(19):1549-51. PubMed ID: 11018081
[No Abstract] [Full Text] [Related]
2. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.
Mandler R; Dadachova E; Brechbiel JK; Waldmann TA; Brechbiel MW
Bioorg Med Chem Lett; 2000 May; 10(10):1025-8. PubMed ID: 10843208
[TBL] [Abstract][Full Text] [Related]
3. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
Mandler R; Wu C; Sausville EA; Roettinger AJ; Newman DJ; Ho DK; King CR; Yang D; Lippman ME; Landolfi NF; Dadachova E; Brechbiel MW; Waldmann TA
J Natl Cancer Inst; 2000 Oct; 92(19):1573-81. PubMed ID: 11018093
[TBL] [Abstract][Full Text] [Related]
4. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
Ochel HJ; Eichhorn K; Gademann G
Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
[No Abstract] [Full Text] [Related]
5. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.
Austin CD; De Mazière AM; Pisacane PI; van Dijk SM; Eigenbrot C; Sliwkowski MX; Klumperman J; Scheller RH
Mol Biol Cell; 2004 Dec; 15(12):5268-82. PubMed ID: 15385631
[TBL] [Abstract][Full Text] [Related]
6. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
Zheng FF; Kuduk SD; Chiosis G; Münster PN; Sepp-Lorenzino L; Danishefsky SJ; Rosen N
Cancer Res; 2000 Apr; 60(8):2090-4. PubMed ID: 10786665
[TBL] [Abstract][Full Text] [Related]
7. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.
Mandler R; Kobayashi H; Davis MY; Waldmann TA; Brechbiel MW
Bioconjug Chem; 2002; 13(4):786-91. PubMed ID: 12121134
[TBL] [Abstract][Full Text] [Related]
8. HER2 in prostate cancer--a viable target or innocent bystander?
Scher HI
J Natl Cancer Inst; 2000 Dec; 92(23):1866-8. PubMed ID: 11106669
[No Abstract] [Full Text] [Related]
9. [Advances in antitumor activity of the hsp90 inhibitor geldanamycin].
Liao ZY; Zhen YS
Yao Xue Xue Bao; 2001 Sep; 36(9):716-20. PubMed ID: 12580116
[No Abstract] [Full Text] [Related]
10. Targeted cancer therapies attempt to hit the bull's-eye.
Miller M
J Natl Cancer Inst; 2000 Dec; 92(23):1878-9. PubMed ID: 11106678
[No Abstract] [Full Text] [Related]
11. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
12. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
14. HERe-2 stay: the continuing importance of translational research in breast cancer.
Sledge GW
J Natl Cancer Inst; 2004 May; 96(10):725-7. PubMed ID: 15150294
[No Abstract] [Full Text] [Related]
15. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
16. [Hsp90: how a chaperone becomes a pharmacological target].
Jacquemin-Sablon A
Bull Cancer; 2003 Nov; 90(11):935-6. PubMed ID: 14706894
[No Abstract] [Full Text] [Related]
17. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat.
Piechocki MP; Pilon SA; Kelly C; Wei WZ
Cell Immunol; 2001 Sep; 212(2):138-49. PubMed ID: 11748930
[TBL] [Abstract][Full Text] [Related]
18. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro.
McLean PJ; Klucken J; Shin Y; Hyman BT
Biochem Biophys Res Commun; 2004 Aug; 321(3):665-9. PubMed ID: 15358157
[TBL] [Abstract][Full Text] [Related]
19. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of novel geldanamycin analogues.
Hu Z; Liu Y; Tian ZQ; Ma W; Starks CM; Regentin R; Licari P; Myles DC; Hutchinson CR
J Antibiot (Tokyo); 2004 Jul; 57(7):421-8. PubMed ID: 15376554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
